Related Experiment Video
Updated: Aug 15, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Maurizio Zangari1, Dixie Esseltine, Choon-Kee Lee
1The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. zangarimaurizio@uams.edu
Abstract:
The prompt response to bortezomib observed in a 63-year-old woman with multiple myeloma was associated with a significant increase in alkaline phosphatase (ALP). After similar elevations were noted in patients responding to bortezomib, thalidomide, dexamethasone combination, ALP levels were analysed in two large bortezomib trials. A statistically significant elevation of ALP from baseline was observed in responding patients (complete and partial responders) within three cycles of therapy. The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Remodeling
Targeted Cancer Therapies
There are several types of targeted therapies against specific...